Additionally, substrate-competitive FTO inhibitors such as FB23-2 and Dac51 have been effective in promoting apoptosis in AML cells and reactivating CD8+T cells by inhibiting tumor glucose metabolism, respectively [332, 333]. Here, CD8A is linked to neoplasm.